April 02, 2026

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted

Conexiant

April 02, 2026

USDA Alerts on Lead in Walmart Chicken Nuggets

Detected lead could be up to five times FDA’s interim reference level for children

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

April 01, 2026

FDA Broadens CFTR Therapy Eligibility

The FDA expanded use of CFTR modulators to include more CF gene variants, increasing treatment eligibility across a wider US patient population.

Conexiant

April 01, 2026

Inside Access, Outside the Rules

Two federal cases highlight alleged misuse of professional roles in health care settings

Conexiant

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 30, 2026

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

Conexiant

March 27, 2026

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Conexiant

March 27, 2026

FDA Drops Age Limit for Neffy

Needle-free epinephrine expands access for younger children meeting weight criteria

Conexiant

March 27, 2026

FDA Approves Gene Therapy for Severe Pediatric LAD-I

Approval expands treatment option for a rare pediatric immunodeficiency

Conexiant